A live-attenuated HSV-2 ICP0- virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Halford, William P ^a   Püschel, Ringo ^a   Gershburg, Edward ^a   Wilber, Andrew ^a   Gershburg, Svetlana ^a   Rakowski, Brandon ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; GLYCOPROTEIN D; GLYCOPROTEIN D2 SUBUNIT VACCINE; HERPES SIMPLEX VACCINE; LIVE ATTENUATED HERPES SIMPLEX 2 VACCINE; LIVE VACCINE; LUCIFERASE; PHOSPHORYL LIPID A; SUBUNIT VACCINE; UNCLASSIFIED DRUG; GLYCOPROTEIN D HERPES SIMPLEX VIRUS TYPE 2; GLYCOPROTEIN D-HERPES SIMPLEX VIRUS TYPE 2; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN G; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; IMAGE ANALYSIS; IN VITRO STUDY; INFECTION RESISTANCE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; SURVIVAL RATE; VAGINITIS; VIRAL EYE INFECTION; VIRUS SHEDDING; WILD TYPE; ANIMAL; ANTIBODY PRODUCTION; GENE DELETION; IMMUNITY; IMMUNIZATION; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; NUCLEAR LOCALIZATION SIGNAL; PATHOGENICITY; THREE DIMENSIONAL IMAGING; VAGINA; VIROLOGY; VIRULENCE;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 2; MUS;

ANIMALS; ANTIBODY FORMATION; FEMALE; GREEN FLUORESCENT PROTEINS; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; IMAGING, THREE-DIMENSIONAL; IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN G; LUCIFERASES; MICE; MICE, INBRED ICR; NUCLEAR LOCALIZATION SIGNALS; SEQUENCE DELETION; VACCINES, ATTENUATED; VACCINES, SUBUNIT; VAGINA; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS; VIRULENCE;

EID: 79952608247     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017748     Document Type: Article

References (90)

1. CDC (2010) Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years-United States, 2005-2008. MMWR Morb Mortal Wkly Rep 59: 456-459.
2. Gottlieb SL, Douglas JM Jr, Foster M, Schmid DS, Newman DR, et al. (2004) Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis 190: 1059-1067.
3. Jonsson MK, Wahren B, (2004) Sexually transmitted herpes simplex viruses. Scand J Infect Dis 36: 93-101.
4. Solomon L, Cannon MJ, Reyes M, Graber JM, Wetherall NT, et al. (2003) Epidemiology of recurrent genital herpes simplex virus types 1 and 2. Sex Transm Infect 79: 456-459.
5. Bernstein DI, (2001) Potential for immunotherapy in the treatment of herpesvirus infections. Herpes 8: 8-11.
6. Bernstein DI, Farley N, Bravo FJ, Earwood J, McNeal M, et al. (2010) The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine 28: 3748-3753.
7. Cunningham AL, Mikloska Z, (2001) The Holy Grail: immune control of human herpes simplex virus infection and disease. Herpes 8 (Suppl 1): 6A-10A.
8. Pollara G, Katz DR, Chain BM, (2004) The host response to herpes simplex virus infection. Curr Opin Infect Dis 17: 199-203.
9. Toka FN, Pack CD, Rouse BT, (2004) Molecular adjuvants for mucosal immunity. Immunol Rev 199: 100-112.
10. Zimmerman DH, Rosenthal KS, (2005) The L.E.A.P.S. approach to vaccine development. Front Biosci 10: 790-798.
11. Weir JP, Bennett M, Allen EM, Elkins KL, Martin S, et al. (1989) Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge. J Gen Virol 70 (Pt 10): 2587-2594.
12. Allen EM, Weir JP, Martin S, Mercadal C, Rouse BT, (1990) Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity. Viral Immunol 3: 207-215.
13. Manickan E, Francotte M, Kuklin N, Dewerchin M, Molitor C, et al. (1995) Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells. J Virol 69: 4711-4716.
14. Kuklin N, Daheshia M, Karem K, Manickan E, Rouse BT, (1997) Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J Virol 71: 3138-3145.
15. Kumaraguru U, Rouse BT, (1998) DNA vaccines for the prophylaxis and modulation of HSV infections. Expert Opin Investig Drugs 7: 219-224.
16. Eo SK, Gierynska M, Kamar AA, Rouse BT, (2001) Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules. J Immunol 166: 5473-5479.
17. Eo SK, Pack C, Kumaraguru U, Rouse BT, (2001) Optimisation of DNA vaccines for the prophylaxis and modulation of herpes simplex virus infections. Expert Opin Biol Ther 1: 213-225.
18. Orr MT, Orgun NN, Wilson CB, Way SS, (2007) Cutting Edge: Recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection. J Immunol 178: 4731-4735.
19. Karem KL, Bowen J, Kuklin N, Rouse BT, (1997) Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens. J Gen Virol 78 (Pt 2): 427-434.
20. Boursnell ME, Entwisle C, Blakeley D, Roberts C, Duncan IA, et al. (1997) A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 175: 16-25.
21. Morrison LA, Da Costa XJ, Knipe DM, (1998) Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology 243: 178-187.
22. Da Costa XJ, Jones CA, Knipe DM, (1999) Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci U S A 96: 6994-6998.
23. Dudek T, Knipe DM, (2006) Replication-defective viruses as vaccines and vaccine vectors. Virology 344: 230-239.
24. Reszka NJ, Dudek T, Knipe DM, (2010) Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine 28: 2754-2762.
25. Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, et al. (2009) Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis 200: 1088-1095.
26. Aurelian L, Kokuba H, Smith CC, (1999) Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Vaccine 17: 1951-1963.
27. Prichard MN, Kaiwar R, Jackman WT, Quenelle DC, Collins DJ, et al. (2005) Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 23: 5424-5431.
28. Brittle EE, Wang F, Lubinski JM, Bunte RM, Friedman HM, (2008) A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine. J Virol 82: 8431-8441.
29. McDermott MR, Smiley JR, Leslie P, Brais J, Rudzroga HE, et al. (1984) Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2. J Virol 51: 747-753.
30. Spector FC, Kern ER, Palmer J, Kaiwar R, Cha TA, et al. (1998) Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J Infect Dis 177: 1143-1154.
31. Meignier B, Longnecker R, Roizman B, (1988) In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 158: 602-614.
32. Watson RJ, Weis JH, Salstrom JS, Enquist LW, (1982) Herpes simplex virus type-1 glycoprotein D gene: nucleotide sequence and expression in Escherichia coli. Science 218: 381-384.
33. Maingay JP, Norval M, Howie SE, (1988) The immune response to glycoproteins of herpes simplex virus. Microbiol Sci 5: 211-215.
34. Nicola AV, Willis SH, Naidoo NN, Eisenberg RJ, Cohen GH, (1996) Structure-function analysis of soluble forms of herpes simplex virus glycoprotein D. J Virol 70: 3815-3822.
35. Higgins TJ, Herold KM, Arnold RL, McElhiney SP, Shroff KE, et al. (2000) Plasmid DNA-expressed secreted and nonsecreted forms of herpes simplex virus glycoprotein D2 induce different types of immune responses. J Infect Dis 182: 1311-1320.
36. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, et al. (2002) Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 347: 1652-1661.
37. Bourne N, Bravo FJ, Francotte M, Bernstein DI, Myers MG, et al. (2003) Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis 187: 542-549.
38. Bourne N, Milligan GN, Stanberry LR, Stegall R, Pyles RB, (2005) Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis 192: 2117-2123.
39. Brans R, Yao F, (2010) Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs. BMC Microbiol 10: 163.
40. Paoletti E, Lipinskas BR, Samsonoff C, Mercer S, Panicali D, (1984) Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A 81: 193-197.
41. Straus SE, Wald A, Kost RG, McKenzie R, Langenberg AG, et al. (1997) Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 176: 1129-1134.
42. Bernstein DI, Cardin RD, Bravo FJ, Strasser JE, Farley N, et al. (2009) Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines. Clin Vaccine Immunol 16: 699-705.
43. Spear PG, (2004) Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol 6: 401-410.
44. Garcon N, Chomez P, Van Mechelen M, (2007) GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 6: 723-739.
45. Martin M, Michalek SM, Katz J, (2003) Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 71: 2498-2507.
46. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, et al. (2007) The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316: 1628-1632.
47. Thompson HS, Davies ML, Watts MJ, Mann AE, Holding FP, et al. (1998) Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A. Vaccine 16: 1993-1999.
48. Cohen J, (2010) Immunology. Painful failure of promising genital herpes vaccine. Science 330: 304.
49. GlaxoSmithKline (2010) GSK provides update on Herpevac trial for women evaluating Simplirix™ (Herpes Simplex Vaccine). http://wwwgskcom/media/pressreleases/2010/2010_pressrelease_10105htm.
50. Halford WP, (2007) Towards an effective genital herpes vaccine: past lessons and future prospects. Future Virology 2: 1-6.
51. Halford WP, Weisend C, Grace J, Soboleski M, Carr DJ, et al. (2006) ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency. Virol J 3: 44.
52. Halford WP, Puschel R, Rakowski B, (2010) Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine. PLoS ONE 5: e12251.
53. Stephenson J, (2000) Genital herpes vaccine shows limited promise. Jama 284: 1913-1914.
54. Parr MB, Kepple L, McDermott MR, Drew MD, Bozzola JJ, et al. (1994) A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab Invest 70: 369-380.
55. Kaushic C, Ashkar AA, Reid LA, Rosenthal KL, (2003) Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol 77: 4558-4565.
56. Laing KJ, Magaret AS, Mueller DE, Zhao L, Johnston C, et al. (2010) Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. J Clin Immunol 30: 703-722.
57. Posavad CM, Remington M, Mueller DE, Zhao L, Magaret AS, et al. (2010) Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J Immunol 184: 3250-3259.
58. Hosken N, McGowan P, Meier A, Koelle DM, Sleath P, et al. (2006) Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J Virol 80: 5509-5515.
59. Wildy P, (1973) Antigens of herpes simplex virus of oral and genital origin. Cancer Res 33: 1465-1468.
60. Haarr L, Skulstad S, (1994) The herpes simplex virus type 1 particle: structure and molecular functions. Review article. Apmis 102: 321-346.
61. Bobrowski PJ, Capiola R, Centifanto YM, (1991) Latent herpes simplex virus reactivation in the guinea pig. An animal model for recurrent disease. Int J Dermatol 30: 29-35.
62. Centifanto-Fitzgerald YM, Rayfield M, Tian PY, Kaufman HE, (1985) Herpes simplex virus latency in the rabbit trigeminal ganglia: ganglionic superinfection. Proc Soc Exp Biol Med 179: 55-67.
63. Centifanto-Fitzgerald YM, Varnell ED, Kaufman HE, (1982) Initial herpes simplex virus type 1 infection prevents ganglionic superinfection by other strains. Infect Immun 35: 1125-1132.
64. Halford WP, Gebhardt BM, (2011) Host interferon: a silent partner in the regulation of herpes simplex virus latency. In: Mossman KL, editors. Viruses and Interferon: current research Hethersett, UK Horizon Scientific Press In press.
65. Dunning R, (1800) Some observations on vaccination, and the inoculated cow-pox. London.
66. Behbehani AM, (1983) The smallpox story: life and death of an old disease. Microbiol Rev 47: 455-509.
67. Sabin AB, (1953) Present status and future possibilities of a vaccine for the control of poliomyelitis. AMA Am J Dis Child 86: 301-310.
68. Takahashi M, Okuno Y, Otsuka T, Osame J, Takamizawa A, (1975) Development of a live attenuated varicella vaccine. Biken J 18: 25-33.
69. Schwarz AJ, (1962) Preliminary tests of a highly attenuated measles vaccine. Am J Dis Child 103: 386-389.
70. Hilleman MR, (1966) Advances in control of viral infections by nonspecific measures and by vaccines, with special reference to live mumps and rubella virus vaccines. Clin Pharmacol Ther 7: 752-762.
71. Du Pan RM, Huggelen C, Peetermans J, Prinzie A, (1968) Clinical trials with a live attenuated rubella virus vaccine; Cendehill 51 strain. Am J Dis Child 115: 658-662.
72. Dick GW, Gee FL, (1952) Immunity to yellow fever nine years after vaccination with 17D vaccine. Trans R Soc Trop Med Hyg 46: 449-458.
73. Girard MP, Osmanov SK, Kieny MP, (2006) A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 24: 4062-4081.
74. Ruprecht RM, Hofmann-Lehmann R, Rasmussen RA, Vlasak J, Xu W, (2000) 1999: a time to re-evaluate AIDS vaccine strategies. J Hum Virol 3: 88-93.
75. Jennner E, (1798) An Inquiry into the Causes and Effects of the Variolae Vaccinae, a Disease Discovered in Some of the Western Counties of England Particularly Gloucestershire, and Known by the Name of "Cowpox". London.
76. Aaby P, Knudsen K, Jensen TG, Tharup J, Poulsen A, et al. (1990) Measles incidence, vaccine efficacy, and mortality in two urban African areas with high vaccination coverage. J Infect Dis 162: 1043-1048.
77. Galea SA, Sweet A, Beninger P, Steinberg SP, Larussa PS, et al. (2008) The safety profile of varicella vaccine: a 10-year review. J Infect Dis 197 (Suppl 2): S165-169.
78. Wattigney WA, Mootrey GT, Braun MM, Chen RT, (2001) Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Pediatrics 107: E83.
79. Mansoor O, Pillans PI, (1997) Vaccine adverse events reported in New Zealand 1990-5. N Z Med J 110: 270-272.
80. Liu M, Schmidt EE, Halford WP, (2010) ICP0 dismantles host cell microtubule networks in herpes simplex virus-infected cells. PLoS ONE 5: e10975.
81. Liu M, Rakowski B, Gershburg E, Weisend CM, Lucas O, et al. (2010) ICP0 antagonizes ICP4-dependent silencing of the herpes simplex virus ICP0 gene. PLoS ONE 5: e8837.
82. Everett RD, Orr A, Preston CM, (1998) A viral activator of gene expression functions via the ubiquitin-proteasome pathway. EMBO Journal 17: 7161-7169.
83. Everett RD, (1984) Trans activation of transcription by herpes virus products: requirement for two HSV-1 immediate-early polypeptides for maximum activity. Embo J 3: 3135-3141.
84. Lauring AS, Jones JO, Andino R, (2010) Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol 28: 573-579.
85. Minor PD, (1993) Attenuation and reversion of the Sabin vaccine strains of poliovirus. Dev Biol Stand 78: 17-26.
86. Krause PR, Klinman DM, (2000) Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nat Med 6: 451-454.
87. Sengupta N, Booy R, Schmitt HJ, Peltola H, Van-Damme P, et al. (2008) Varicella vaccination in Europe: are we ready for a universal childhood programme? Eur J Pediatr 167: 47-55.
88. Samaniego LA, Neiderhiser L, DeLuca NA, (1998) Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 72: 3307-3320.
89. Sprague ER, Martin WL, Bjorkman PJ, (2004) pH dependence and stoichiometry of binding to the Fc region of IgG by the herpes simplex virus Fc receptor gE-gI. J Biol Chem 279: 14184-14193.
90. Halford WP, Halford KJ, Pierce AT, (2005) Mathematical analysis demonstrates that interferons-beta and-gamma interact in a multiplicative manner to disrupt herpes simplex virus replication. J Theor Biol 235: 439-454.